Vertex Pharmaceuticals
VRTX
1,687 hedge funds and large institutions have $106B invested in Vertex Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 151 funds opening new positions, 679 increasing their positions, 596 reducing their positions, and 104 closing their positions.
45% more first-time investments, than exits
New positions opened: 151 | Existing positions closed: 104
24% more call options, than puts
Call options by funds: $851M | Put options by funds: $684M
14% more repeat investments, than reductions
Existing positions increased: 679 | Existing positions reduced: 596
13% more funds holding in top 10
Funds holding in top 10: 15 → 17 (+2)
1% more funds holding
Funds holding: 1,668 → 1,687 (+19)
3% less capital invested
Capital invested by funds: $110B → $106B (-$3.45B)
1.71% less ownership
Funds ownership: 95.26% → 93.55% (-1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$1.78B |
| 2 |
JP Morgan Chase
New York
|
+$463M |
| 3 |
Goldman Sachs
New York
|
+$310M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$183M |
| 5 |
Two Sigma Investments
New York
|
+$174M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$685M |
| 2 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$405M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$284M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$273M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$242M |
VRTX Hedge Fund Activity: Q1 2026 in Review
1,687 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q1 2026, worth a combined $106B — down 3.2% from $110B a quarter earlier.
Buyers outnumbered sellers: 151 funds opened new VRTX positions and 104 closed out — a net gain of 47 holders — while 679 added to existing stakes and 596 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $1.78B. The largest seller was Victory Capital Management, cutting an estimated $685M.
- 1,687 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q1 2026, up from 1,668 in Q4 2025.
- Funds reported $106B of Vertex Pharmaceuticals stock for Q1 2026, down 3.2% quarter-over-quarter.
- 151 funds opened new Vertex Pharmaceuticals positions in Q1 2026 and 104 closed out, a net change of +47 holders.
- The largest Vertex Pharmaceuticals buyer in Q1 2026 was Capital Research Global Investors, an estimated $1.78B added.
- The largest Vertex Pharmaceuticals seller in Q1 2026 was Victory Capital Management, an estimated $685M sold.
Based on aggregated 13F filings for Q1 2026.